1 Reason Every Investor Should Know About AbbVie (ABBV)

With patent-protected market exclusivity for their products, pharmaceutical companies reliably produce profits that they aren't shy about distributing to shareholders. In an industry already known for relatively strong dividend payout raises, AbbVie (NYSE: ABBV) stands out with a quarterly payment that has soared 221.6% over the past decade.Image source: Getty Images.An ability to retain exclusivity for its former lead drug is how AbbVie delivered a 494% total return over the past decade. The company spun off from Abbott Laboratories in 2013 to limit the parent's exposure to a looming patent cliff for Humira, an injectable anti-inflammation treatment for people with arthritis, psoriasis, and other autoimmune disorders that launched in 2003.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool